(PharmaNewsWire.Com, November 10, 2020 ) According to research report the global Artificial Heart Valves Market is projected to reach $8.86 Billion by 2022 from $4.84 Billion in 2017, at a CAGR of 12.9%.
Globally, the artificial heart valves market is witnessing growth due to factors such as rising geriatric population and the subsequent growth in the prevalence of heart valve disease (HVD), regulatory approvals for new and advanced prosthetic heart valves, increasing government funding for heart valve research, rising awareness about HVD, and favorable reimbursement scenario for prosthetic heart valves.
North America to Command the Largest Prosthetic Heart Valves Market Share in 2017
Based on region, the Prosthetic Heart Valves Market is divided into North America, Europe, Asia-Pacific, and the Rest of the World. In 2017, North America is expected to account for the largest share of the global market. Factors such as the rapid growth in the aging population and prevalence of valvular heart diseases, favorable reimbursement scenario, and rising product approvals for heart valves are contributing to the growth of the North American Prosthetic Heart Valves Market are driving the growth of the North American artificial Heart Valves Market.
The Transcatheter Heart Valves Segment Is Expected to Account for the Largest Share of the Prosthetic Heart Valves Market in 2017
Based on the type of valve, the artificial Heart Valves Market is segmented into transcatheter heart valves, tissue heart valves, and mechanical heart valves. The transcatheter heart valves segment is expected to command the largest market share in 2017. The large share of this segment can be attributed to factors such as the rising prevalence of aortic stenosis, increasing pool of patients owing to approvals for extended valve indications, and technological advancements. The preference for transcatheter heart valves is expected to see high growth in the future as they are implanted through a minimally invasive procedure while the other valve types require open-heart surgery.
Medtronic plc (Ireland), Edwards Lifesciences Corporation (U.S.), Boston Scientific Corporation (U.S.), St. Jude Medical, Inc. (an Abbott Laboratories Company) (U.S.), LivaNova PLC (U.K.), Symetis SA (Switzerland), Jenavalve Technology, Inc. (Germany), CryoLife, Inc. (U.S.), TTK Healthcare Limited (India), Colibri Heart Valve, LLC (U.S.), Lepu Medical Technology Co., Ltd. (China), and Braile Biomédica (Brazil) are the prominent players in the global Artificial Heart Valves Market.
A number of key players in this market are competing against each other in order to expand their existing customer base. The artificial heart valves market, by type, is categorized as transcatheter heart valves, tissue heart valves, and mechanical heart valves. In 2016, Edwards Lifesciences Corporation (U.S.) and Medtronic plc (Ireland) dominated both, the transcatheter heart valves and the tissue heart valves market segments; the mechanical heart valves market was dominated by St. Jude Medical, Inc. (an Abbott Laboratories Company) (U.S.) and LivaNova PLC (U.K.).
Contact: Mr. Aashish Mehra MarketsandMarkets™ INC. 630 Dundee Road Suite 430 Northbrook, IL 60062 USA: +1-888-600-6441 sales@marketsandmarkets.com
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
